Vascular pathophysiology of Alzheimer's disease

Current Alzheimer Research

Volumn 11, Issue 1, 2014, Pages 1-3

  Laske, Christoph ^a,b   Stellos, Konstantinos ^c,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BRAIN BLOOD VESSEL; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NERVE DEGENERATION; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE; VASCULITIS;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN; CEREBROVASCULAR DISORDERS; HUMANS; PLAQUE, AMYLOID;

EID: 84891750174     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205010666131120101608     Document Type: Editorial

References (21)

1. Bergeron C, Ranalli PJ, Miceli PN. Amyloid angiopathy in Alzheimer's disease. Can J Neurol Sci 14(4): 564-569 (1987).
2. Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 135: 3749-3756 (2012).
3. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322: 1447-1451 (2001).
4. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66: 343-348 (2009).
5. Roselli F, Tartaglione B, Federico F, Lepore V, Defazio G, Livrea P. Rate of MMSE score change in Alzheimer's disease: influence of education and vascular risk factors. Clin Neurol Neurosurg 111: 327-330 (2009).
6. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-817 (1997).
7. Song IU, Kim JS, Kim YI, Eah KY, Lee KS. Clinical significance of silent cerebral infarctions in patients with Alzheimer disease. Cogn Behav Neurol 20: 93-98 (2007).
8. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, et al. Cerebrovascular lesions induce transient betaamyloid deposition. Brain 134(Pt 12): 3697-3707 (2011).
9. Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4(2): 191-197 (2007).
10. Nagababu E, Usatyuk PV, Enika D, Natarajan V, Rifkind JM. Vascular endothelial barrier dysfunction mediated by amyloid-beta proteins. J Alzheimers Dis 17(4): 845-854 (2009).
11. Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM. Soluble amyloidbeta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener 5 (15): 1-12 (2010).
12. Rancillac A, Geoffroy H, Rossier J. Impaired neurovascular coupling in the APPxPS1 mouse model of Alzheimer's disease. Curr Alzheimer Res 9(10):1221-1230 (2012).
13. Lee CW, Shih YH, Kuo YM. Cerebrovascular pathology and amyloid plaque formation in Alzheimer's disease. Curr Alzheimer Res 11(1): 4-10 (2013).
14. van den Abeelen ASSM, Lagro J, van Beek AHEA, Claasen JAHR. Impaired cerebral autoregulation and vasomotor reactivity in Alzheimer's disease. Curr Alzheimer Res 11(1): 11-17 (2013).
15. Lyros E, Bakogiannis C, Liu Y, Fassbender K. Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer's disease. Curr Alzheimer Res 11(1): 18-26 (2013).
16. Sopova K, Gatsiou A, Stellos K, Laske C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's Disease: From pathophysiology to novel treatment strategies. Curr Alzheimer Res 11(1): 27-39 (2013).
17. Spiess PE, Verbeek MM, Sjogren MJC, Leeuw FE, Claasen JAHR. Alzheimer biomarkers and clinical Alzheimer disease were not associated with increased cerebrovascular disease in a memory clinic popylation. Curr Alzheimer Res 11(1): 40-46 (2013).
18. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162: 2046-2052 (2002).
19. Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 16: 883-892 (2008).
20. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73: 674-680 (2009).
21. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128 (2010).